Tiotropium Bromide Capsule
NDC Package 68180-964-12
Package Information
Tiotropium Bromide capsules is tiotropium bromide inhalation powder is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. This formulation utilizes a capsule delivery system. Marketed by Lupin Pharmaceuticals, Inc., this product is identified by NDC 68180-964 and is authorized under FDA application ANDA211287.
Identification & Billing
- RxCUI: 485032 - tiotropium 18 MCG Inhalation Powder
- RxCUI: 485032 - tiotropium 0.018 MG Inhalation Powder
- RxCUI: 485032 - tiotropium 18 MCG (tiotropium bromide 22.5 MCG) Inhalation Powder
Clinical Specifications
- Oral - Administration to or by way of the mouth.
- Respiratory (inhalation) - Administration within the respiratory tract by inhaling orally or nasally for local or systemic effect.
Regulatory & Marketing
Hierarchy Structure
- 68180 - Lupin Pharmaceuticals, Inc.
- 68180-964 - Tiotropium Bromide
- 68180-964-12 - 3 BLISTER PACK in 1 CARTON / 10 CAPSULE in 1 BLISTER PACK
- 68180-964 - Tiotropium Bromide
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 68180-964-12 identifies a specific commercial package of 3 blister pack in 1 carton / 10 capsule in 1 blister pack of Tiotropium Bromide, a human prescription drug labeled by Lupin Pharmaceuticals, Inc.. This capsule is formulated for oral; respiratory (inhalation) use and contains tiotropium bromide monohydrate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Lupin Pharmaceuticals, Inc. on August 16, 2023. The current certification is valid through December 31, 2027.
How is this Lupin Pharmaceuticals, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 68180096412. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.